Records 141–180 of 290. Open a study to inspect the full evidence record. Source links lead directly to the publication. Updated 19 October 2026.
Cardiovascular and metabolic health (13) · Uric acid and gout (2) · Forms, absorption and food sources (6) · Inflammation and clinical symptoms (3) · Hormones and reproductive health (1) · Skin and topical formulations (3) · Immunity and respiratory health (1) · Safety, interactions and special populations (6) · Allergies, histamine and mast cells (1) · Prostate and urinary health (1) · Senescence and longevity (1) · Exercise and recovery (1) · Evidence reviews and human mechanisms (1)
Post hoc analysis of a randomized double-blind crossover trial. Quercetin reduced methylglyoxal by about 11%, without significant changes in the other measured dicarbonyls or advanced-glycation products.
Systematic review and meta-analysis of randomized trials. Overall LDL, HDL, and triglyceride outcomes were not significantly improved; selected dose-duration subgroups showed triglyceride changes.
Randomized double-blind placebo-controlled crossover meal study. Quercetin did not attenuate post-meal blood pressure, vascular or metabolic responses.
Randomized double-blind placebo-controlled crossover trial. Leptin, adiponectin, inflammatory markers, glucose and insulin did not improve. Measured short-term safety markers did not change.
Randomized double-blind placebo-controlled crossover nutrition trial. ALA and EPA increased with both interventions. Quercetin did not add a favorable fatty-acid effect or improve DHA status.
Randomized adjunctive usual-care controlled trial. Some ischemia, ectopic-beat and diastolic measurements favored added quercetin, while both patient groups improved on several measures.
Original sources: PubMed
Randomized controlled acute dose-response crossover study. Metabolite exposure rose with dose, but endothelial function, blood pressure and nitric-oxide measures did not improve.
Randomized double-blind placebo-controlled crossover trial. Quercetin did not improve the primary flow-mediated dilation endpoint, insulin resistance or other measured cardiovascular risk factors.
Randomized double-blind placebo-controlled crossover trial; secondary biomarker report. Quercetin reduced selected inflammatory and endothelial activation biomarkers, including soluble E-selectin and interleukin-1 beta.
Randomized double-blind placebo-controlled crossover trial. Overall blood-pressure outcomes were null. A hypertensive subgroup showed a modest reduction in 24-hour systolic pressure.
Placebo-comparator dietary pilot. Selected cholesterol, waist, and antioxidant measures improved in the onion-juice group.
Randomized double-blind placebo-controlled crossover experiment. Brachial artery diameter increased at 5 hours, while blood pressure and circulating nitric oxide metabolites did not change.
Double-blind placebo-controlled crossover trial with APOE subgroup analysis. Endothelial function did not improve. Selected anthropometric, postprandial pressure, and lipid measures changed, while tumor necrosis factor alpha increased.
Controlled adjunctive clinical study. The quercetin group showed favorable echocardiographic, urate, pressure and estimated kidney-function changes.
Original sources: PubMed
Randomized double-blind placebo-controlled crossover trial. Uric acid decreased by about 26.5 micromol/L, while fasting glucose, pressure and urinary uric-acid excretion did not change.
Narrative review of human bioavailability and individual variation. Absorption and metabolite profiles vary substantially between people, with possible contributions from gut metabolism and host factors.
Randomized single-blind diet-controlled crossover pharmacokinetic trial. Measured quercetin exposure and peak concentrations were higher after the onion-skin extract.
Four-way crossover food-matrix absorption pilot. The tested apple preparations and reference capsule produced broadly similar exposure, with matrix-related differences in concentration profiles.
Narrative review of pharmacokinetics and bioavailability determinants. The review describes low and variable exposure and strategies that might improve it.
Randomized single-blind crossover pharmacokinetic study. The onion meal produced similar urinary quercetin excretion despite a much smaller ingested amount.
Randomized crossover food-matrix absorption study. Pectin increased urinary recovery of quercetin metabolites, with effects varying by amount and methylation level.
Randomized double-blind placebo-controlled trial. Pain, stiffness, disease-activity and disability scores and hs-TNF-alpha favored quercetin. Joint-count and ESR differences were not significant.
Randomized active-comparator clinical study. Both groups improved in symptoms and electrophysiology; a pain-regression trend favored the nutraceutical.
Randomized double-blind placebo-controlled rheumatoid-arthritis trial. Oxidative-stress measures, CRP, and blood pressure did not differ significantly between groups.
Randomized double-blind placebo-controlled PCOS trial. Adiponectin measures increased and HOMA-IR, testosterone and LH decreased relative to placebo.
Randomized double-blind placebo-controlled oncology-support trial. Mucositis incidence did not differ significantly. Reported mucositis severity was higher in the quercetin group, and healing time did not improve.
Single-blind controlled topical challenge study. The quercetin cream reduced selected erythema and wheal measures after experimental irritation.
Narrative review of topical quercetin and formulation design. Quercetin has experimental skin effects, but solubility and penetration complicate topical delivery.
Systematic review and meta-analysis of randomized trials. Circulating CRP decreased modestly in the pooled analysis.
Open-label phase 1 dose-escalation trial. The investigators reported short-term tolerability and viral-load reductions in a subset, without significant liver-enzyme changes.
Open-label two-period crossover interaction study. Quercetin did not significantly alter cefprozil pharmacokinetics in this cohort.
Human crossover pharmacokinetic interaction study. A single dose did not alter midazolam pharmacokinetics. Repeated quercetin showed a nonsignificant trend toward lower oral midazolam exposure; intravenous results differed.
Controlled maternal dietary-exposure study. Quercetin concentrations in milk increased after the meal, demonstrating transfer from maternal dietary intake.
Human crossover pharmacokinetic interaction study. Average talinolol peak concentration and exposure decreased without statistically significant group differences; some individuals had larger reductions.
Two-phase human pharmacokinetic interaction study. Quercetin inhibited caffeine metabolism under the tested schedule; the two selected genotype groups did not differ significantly.
Narrative review of anti-allergic mechanisms. The review describes inhibition of selected mast-cell and inflammatory pathways and possible anti-allergic applications.
Prospective three-regimen comparative study. The combined oral and estrogen regimen showed greater recurrence and symptom improvements than the single regimens.
Senolytic discovery experiments in cells and mouse models. Quercetin and dasatinib had different cell-type effects; the combination reduced selected senescence markers and improved some mouse functional outcomes.
Randomized placebo-controlled four-arm supplementation trial. Neither quercetin nor its combination improved measured physical performance or antioxidant status.
Narrative review of molecular actions and clinical translation. The review summarizes multiple proposed actions while emphasizing the need for better human trials.
Design tiers organize different kinds of evidence; read the source-specific limitations before applying a result. The full library is curated by Biohack Blueprint. Each evidence record lists its editorial author and reviewers.
